Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia

Expert Review of Anticancer Therapy

Volumn 11, Issue 2, 2011, Pages 151-160

  Reagan, John L ^a   Castillo, Jorge J ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

CD20; chronic lymphocytic leukemia; CLL; monoclonal antibody; ofatumumab

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; FLAVOPIRIDOL; FLUDARABINE; FLUDARABINE PHOSPHATE; LENALIDOMIDE; LUMILIXIMAB; METHYLPREDNISOLONE; MITOXANTRONE; OBLIMERSEN; OFATUMUMAB; PARACETAMOL; PENTOSTATIN; RITUXIMAB; STEROID;

ANEMIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); COUGHING; CYTOLYTIC HEPATITIS; DIAPHORESIS; DIARRHEA; DRUG BINDING; DRUG BINDING SITE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HERPES ZOSTER; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; LEUKOENCEPHALOPATHY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PNEUMONIA; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; RIGOR; SIDE EFFECT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECURRENCE; VIDARABINE;

EID: 79952156766     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.223     Document Type: Review

References (49)

1. Rawstron AC, Bennett FL, O'Connor SJ et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N. Engl. J. Med. 359(6), 575-583 (2008).
2. Castillo J, Perez K. The role of of atumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies. J. Blood Med. 1, 1-8 (2010).
3. Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343(24), 1750-1757 (2000).
4. Eichhorst BF, Busch R, Stilgenbauer S et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114(16), 3382-3391 (2009).
5. Knauf W, Lissichkov T, Aldaoud A et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 27(26), 4378-4384 (2009).
6. Stilgenbauer S, Zenz T, Winkler D et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 27(24), 3994-4001 (2009).
7. Hillmen P, Skotnicki A, Robak T et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25(35), 5616-5623 (2007).
8. Czuczman M, Gregory S. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk. Lymph. 51(6), 983-9940 (2010).
9. Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp. Hematol. 36(7), 755-768 (2008).
10. Huhn D, von Schilling C, Wilhelm M et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5), 1326-1331 (2001).
11. Hainsworth J, Litchy S, Barton J et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 21(9), 1746-1751 (2003).
12. Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet 376(9747), 1164-1174 (2010).
13. Robak T, Dmoszynska A, Solal-Cligny P et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 28(10), 1756-1765 (2010).
14. Lin TS, Ruppert AS, Johnson AJ et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J. Clin. Oncol. 27(35), 6012-6018 (2009).
15. Chanan-Khan A, Miller K, Musial L et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a Phase II study. J. Clin. Oncol. 24(34), 5343-5349 (2006).
16. Tam CS, O'Brien S, Lerner S et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk. Lymph. 48(10), 1931-1939 (2007).
17. Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104(6), 1793-1800 (2004).
18. Pawluczkowycz AW, Beurskens FJ, Beum PV et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 183(1), 749-758 (2009).
19. Teeling J, Mackus WJ, Wiegman LJ et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177(1), 362-371 (2006).
20. Beum PV, Lindorfer MA, Beurskens F et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J. Immunol. 181(1), 822-832 (2008).
21. de Haij S, Jansen JH, Boross P et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 70(8), 3209-3217 (2010).
22. Craigen JL, Mackus WJ, Engleberts P et al. Ofatumumab, a human mAb targeting a membrane-proximal small-loop epitope on CD20, induces potent NK cell-mediated ADCC. ASH Ann. Meeting Abstr. 114(22), 1725 (2009).
23. Bleeker WK, Munk ME, Mackus WJ et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br. J. Haematol. 140(3), 303-312 (2008).
24. Coiffier B, Losic N, Rønn BB et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a Phase 1/2 study. Br. J. Haematol. 150(1), 58-71 (2010).
25. Osterborg A, Ronn BB, Jewell RC et al. Correlation between serum ofatumumab concentrations, baseline patient characteristics and clinical outcomes in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL) treated with single-agent ofatumumab. ASH Ann. Meeting Abstr. 114(22), 3433 (2009).
26. Wierda WG, Kipps TJ, Durig J et al. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, Phase II trial. ASH Ann. Meeting Abstr. 114(22), 207 (2009).
27. Coiffier B, Lepretre S, Pedersen L et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a Phase 1-2 study. Blood 111(3), 1094-1100 (2008).
28. Wierda W, Kipps T, Mayer J et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28(10), 1749-1755 (2010).
29. Flinn I, Neuberg D, Grever M et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol. 25(7), 793-798 (2007).
30. Robak T, Jamroziak K, Gora-Tybor J et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a Phase III randomized study by the polish adult leukemia group (PALG-CLL3 study). J. Clin. Oncol. 28(11), 1863-1869 (2010).
31. Robak T, Blonski JZ, Gora-Tybor J et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 108(2), 473-479 (2006).
32. Frankfurt O, Hamilton E, Duffey S et al. Alemtuzumab and rituximab combination therapy for patients with untreated CLL - a Phase II trial. ASH Ann. Meeting Abstr. 112(11), 2098 (2008).
33. Kay N, Wu W, Kabat B et al. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer 116(9), 2180-2187 (2010).
34. Kay N, Geyer S, Call T et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109(2), 405-411 (2007).
35. Parikh SA, Keating M, O'Brien S et al. Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemia. Blood (ASH Ann. Meeting Abstr.) 114(22), 208 (2009).
36. Fischer K, Cramer P, Stilgenbauer S et al. Combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter Phase II trial of the German CLL Study Group (GCLLSG). ASH Ann. Meeting Abstr. 114(22), 205 (2009).
37. O'Brien S, Moore J, Boyd T et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, Phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J. Clin. Oncol. 27(31), 5208-5212 (2009).
38. Byrd JC, Kipps TJ, Flinn IW et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 115(3), 489-495 (2010).
39. Koppler H, Heymanns J, Pandorf A, Weide R. Bendamustine plus mitoxantrone - a new effective treatment for advanced chronic lymphocytic leukaemia: results of a Phase I/II study. Leuk. Lymph. 45(5), 911-913 (2004).
40. Engert A, Elter T, Borchmann P et al. Concomitant treatment of patients with relapsed/refractory CLL using a combination of fludarabine and alemtuzumab is highly effective: final results of a Phase-II study. ASCO Meeting Abstracts 23(16 Suppl.), 6558 (2005).
41. Elter T, James R, Stilgenbauer S et al. Chemoimmuno-therapy with fludarabine, cyclophosphamide and alemtuzumab (FC-Cam) in patients with relapsed or genetic high-risk CLL: final analysis of the CLL2L trial of the German CLL Study Group. ASH Ann. Meeting Abstr. 114(22), 209 (2009).
42. Lamanna N, Heaney ML, Brentjens RJ, Jurcic JG, Weiss MA. Pentostatin, cyclophosphamide, rituximab, and mitoxantrone (PCRM): a new highly active regimen for patients with chronic lymphocytic leukemia (CLL) previously treated with PCR or FCR. ASH Ann. Meeting Abstr. 110(11), 3115 (2007).
43. Zent CS, Call TG, Shanafelt TD et al. Alemtuzumab and rituximab for initial treatment of high risk, early stage chronic lymphocytic leukemia (CLL). ASH Ann. Meeting Abstr. 110(11), 2050 (2007).
44. Fischer K, Stilgenbauer S, Schweighofer CD et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre Phase II trial of the German CLL Study Group (GCLLSG). ASH Ann. Meeting Abstr. 112(11), 330 (2008).
45. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J. Clin. Oncol. 28(21), 3525-3530 (2010).
46. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. National Cancer Institute. Bethesda, MD, USA http://seer.cancer.gov/ csr/1975-2007 Based on the November 2009 SEER data submission that was posted to the SEER website in 2010.
47. ClinicalTrials.gov. A Service of the US National Institutes of Health www.clinicaltrials.gov
48. US FDA: Ofatumumab www.fda.gov/AboutFDA/CentersOffices/CDER/ucm188221.htm
49. European Medicines Agency: public summary of opinion on orphan designation: ofatumumab for the treatment of chronic lymphocytic leukaemia (2010) www.ema.europa.eu/docs/en-GB/document-library/Orphan-designation/2009/10/ WC500006208.pdf